Abstract:Key PointsIn recent years, several G protein-coupled receptors (GPCRs) have been identified that are activated by energy substrates such as fatty acids and sucrose, or by metabolic intermediates such as acetate, lactate or ketone bodies.These carbohydrate or lipid metabolites, by activating specific GPCRs, function in a hormone-like fashion in addition to their role as carriers of energy.Metabolite receptors sense metabolic activity or levels of energy substrates and control the secretion of metabolic hormones or regulate the metabolic activity of particular cells.Synthetic ligands of the heterodimeric sweet receptor taste receptor type 1 member 2 (TAS1R2)–TAS1R3, which is a receptor for mono- and disaccharides, are used as artificial sweeteners but may have additional metabolic functions, as TAS1R2–TAS1R3 appears to be also involved in non-gustatory metabolic functions.The long-chain fatty acid receptors free fatty acid receptor 1 (FFA1; (also known as GPR40) and GPR120 (also known as omega-3 fatty acid receptor 1) mediate beneficial effects by promoting glucose-induced insulin secretion and by inhibiting inflammatory signalling in immune cells, respectively.The short-chain fatty acid receptors FFA2 (also known as GPR43) and FFA3 (also known as GPR41) appear to link the gut microbiota to metabolic and immune functions. Whether these receptors can be exploited therapeutically is currently not clear.Succinate receptor 1 (SUCNR1; also known as GPR91), which is activated by the citric acid cycle intermediate succinate (released by cells following cellular stress or hypoxia), is involved in the regulation of blood pressure, retinal angiogenesis and immune functions.Of the hydroxycarboxylic acid receptors, which are activated by ketone bodies or lactate, hydroxycarboxylic acid receptor 2 (HCA2) — which is also activated by nicotinic acid — in particular is of pharmacological interest as it mediates some anti-dyslipidaemic effects as well as anti-inflammatory effects, which can be used to reduce the progression of atherosclerosis and potentially other diseases.Several of these receptors have been tested as targets for drugs to treat particular metabolic diseases, and various synthetic ligands have been developed in recent years. Agonists of FFA1 and HCA2 are currently being tested in clinical trials.

G protein-coupled receptors as regulators of glucose homeostasis and therapeutic targets for diabetes mellitus.

G Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus

G protein-coupled receptors as new therapeutic targets for type 2 diabetes

G Protein-Coupled Receptors in Energy Homeostasis

G protein-coupled receptors as regulators of energy homeostasis.

G protein-coupled receptors: signalling and regulation by lipid agonists for improved glucose homoeostasis

Fatty acid receptors as new therapeutic targets for diabetes

G protein-coupled receptors: potential therapeutic targets for diabetic nephropathy.

GPCRs involved in metabolic diseases: pharmacotherapeutic development updates

The Role of G Protein-Coupled Receptors and Receptor Kinases in Pancreatic {beta}-Cell Function and Diabetes

Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes

Lipid receptors and islet function: therapeutic implications?

Targeting lipid GPCRs to treat type 2 diabetes mellitus — progress and challenges

Novel advances in understanding fatty acid-binding G protein-coupled receptors and their roles in controlling energy balance

GPR40-a potential target for diebete mellitus

Pancreatic regulation of glucose homeostasis

G protein-coupled receptors for energy metabolites as new therapeutic targets

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

GPCR-mediated effects of fatty acids and bile acids on glucose homeostasis

Class B1 GPCRs: Insights into Multi-Receptor Pharmacology for the Treatment of Metabolic Disease

Advances of G protein coupled receptor 119 agonists and their structure-activity relationship